Mohammad Naghavi Behzad
1, Nariman Nezami
2, Reza Piri
1, Javid Safa
2, Behzad Salari
2, Nadereh Rashtchi Zadeh
3, Amir Ghorbanihaghjo
2*1 Research Center for Philosophy and History of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran
2 Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
3 Biotechnology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
Abstract
Background & Objectives: This study was done to investigate the effect of lovastatin therapy on paraoxonase 1 (PON1) and arylesterase (ARE) activities, and low-density lipoprotein cholesterol (LDL-C) susceptibility to oxidation in people with type 2 diabetic nephropathy (T2DN). & Methods: Lovastatin (20 mg/day) was administered to 30 people with T2DN for 90 days and then withdrawn for 30 days. PON1 and ARE activities were measured by the spectrophotometric method. Susceptibility of LDL-C to oxidation was determined as the production of conjugated dienes. Results: After 90 days of lovastatin intervention, PON1 and ARE activities and LDL-C lag phase were significantly increased (p=0.004, 0.002, and b0.001). After 30 days of lovastatin withdrawal, PON1 and ARE activities and LDL-C lag phase had not changed significantly. Conclusion: Lovastatin therapy improves PON1 and ARE activities, and LDL-C susceptibility to oxidation. Despite withdrawal of lovastatin, PON1 and ARE activities, and LDL-C susceptibility to oxidation remain unchanged for a long period of time in people with T2DN.